Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Dynamic LED light versus static LED light for depressed inpatients: results from a randomized feasibility trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence rates of dilated cardiomyopathy in adult first-degree relatives versus matched controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Early Coronary Atherosclerosis in Women With Previous Preeclampsia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. COVID-19 mRNA vaccination and myocarditis or pericarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Niklas Dyrby Johansen
  • Daniel Modin
  • Joshua Nealon
  • Sandrine Samson
  • Camille Salamand
  • Carsten Schade Larsen
  • Brian L Claggett
  • Scott D Solomon
  • Martin J Landray
  • Gunnar H Gislason
  • Lars Køber
  • Jens Ulrik Stæhr Jensen
  • Pradeesh Sivapalan
  • Lasse Skafte Vestergaard
  • Palle Valentiner-Branth
  • Tyra Grove Krause
  • Tor Biering-Sørensen
View graph of relations

BACKGROUND: High-dose influenza vaccines provide better protection against influenza infection than standard-dose in persons aged 65 years and above; however, in most countries, high-dose vaccines are not widely implemented. Assessing the relative effectiveness of high-dose compared to standard-dose vaccines on hospitalizations and mortality would enable more robust public health and cost-effectiveness estimates. This study aims to investigate the feasibility of conducting a pragmatic randomized clinical trial in Denmark comparing high-dose to standard-dose vaccines utilizing existing vaccination infrastructure and the Danish nationwide health registries for data collection.

METHODS: The DANFLU-1 trial (NCT05048589) is a pragmatic, open-label, active-controlled randomized trial randomizing Danish citizens aged 65-79 years to either high-dose quadrivalent influenza vaccine or standard-dose quadrivalent influenza vaccine. The study utilizes the infrastructure of a private vaccination provider (Danske Lægers Vaccinations Service) for recruitment, inclusion, randomization, and vaccination. All collection of baseline and follow-up data including safety monitoring is performed centrally by the Department of Cardiology at Herlev and Gentofte Hospital, Copenhagen, Denmark using the Danish nationwide health registries. The study aims to include 40,000 participants during the 2021/2022 influenza season. The primary endpoints address feasibility and include the number of participants enrolled, randomization balance, and representativeness compared to the Danish general population. Relative vaccine effectiveness will also be assessed, however, this feasibility study is not powered for clinical outcomes and may be affected by the COVID-19 pandemic.

DISCUSSION: The DANFLU-1 study is investigating the feasibility of conducting a large-scale pragmatic clinical trial in Denmark utilizing existing infrastructure and the Danish nationwide registries. This will provide valuable insight, especially for potential future fully powered vaccine trials, but also for trials wishing to investigate other interventions.

TRIAL REGISTRATION: Clinicaltrials.gov : NCT05048589 , registered September 17, 2021.

Original languageEnglish
Article number87
JournalPilot and Feasibility Studies
Volume8
Issue number1
Pages (from-to)87
ISSN2055-5784
DOIs
Publication statusPublished - 21 Apr 2022

Bibliographical note

© 2022. The Author(s).

ID: 77582057